The US Food and Drug Administration (FDA) has cleared Vesalio’s pVasc NET, expanding the company’s existing pVasc technology portfolio for the treatment of thromboembolic disease in the peripheral vasculature.

The Texas-based company’s newly cleared device incorporates a fine-pore, dual-layer filter within the distal portion of the device, designed to capture and retain clot fragments following retrieval while preserving the core features of its proprietary ‘drop zone’ architecture.

Vesalio’s drop zone architecture refers to the proprietary clot-capture design incorporated into existing devices within its mechanical thrombectomy portfolio. Instead of relying on a standard mesh that pins a blood clot against the artery wall, the drop zone design uses large, recessed pockets – referred to as drop zones – along the device that trap and cradle thrombi inside the structure.